市場調查報告書
商品編碼
1008096

全球腎癌診斷和治療市場(2020-2026)

Global Kidney Cancer Diagnostics and Therapeutics Market 2020-2026

出版日期: | 出版商: Orion Market Research Pvt Ltd | 英文 | 商品交期: 2-3個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

全球腎癌診斷和治療市場:按癌症類型(透明細胞 RCC(腎細胞癌)、乳頭狀 RCC、髮色團 RCC、尿路癌/移行細胞癌、以及其他腎臟(維爾姆斯瘤、腎肉瘤、集合)管 RCC))、按診斷方法(活檢、影像等)、按治療(靶向治療、免疫治療、冷凍切除)、按地區、市場規模預測、份額和趨勢分析報告

在預測期內,全球腎癌診斷和治療市場正以 6.8% 的顯著複合年增長率增長。推動市場增長的主要特徵包括腎癌患病率的增加、生活方式的改變(如吸煙和飲酒)、體力活動的減少以及用於治療腎癌的新藥的批准。...此外,對於營銷人員而言,免疫療法將成為市場機遇。免疫療法和化學療法等各種療法的技術開發和藥物擴張的不斷現代化有望支持全球腎癌市場的增長。免疫療法等治療方法的發展有望創造顯著的市場前景。

免疫療法的危害比化療小□□,因此更適合老年人。免疫療法比化學療法反應更快、更一致。閒置地區大量未確診的患者群體可以為市場經銷商創造有利的機會。然而,對治療腎癌的仿製藥的日益偏好以及與品牌藥物相關的特殊成本預計將抑制未來的市場增長。

此外,2019 年 5 月,輝瑞 (Pfizer) 的 BAVENCIO (avelumab) Plus Inlyta 獲得美國 (FDA) 批准,該藥物可用於治療晚期腎細胞癌 (RCC) 患者。該藥物是最早與 INLYTA 聯合使用的抗 PD-L1 藥物之一。 III 期試驗顯示,與舒尼替尼相比,該組合可顯著降低晚期 RCC 患者疾病進展或死亡的可能性 31%,並將無進展生存期延長 5.4 個月。

分部展望

全球腎癌診斷和治療市場根據治療、診斷方法和癌症類型進行劃分。根據治療,市場分為靶向治療、免疫治療和冷凍治療。免疫治療藥物組合、免疫治療和定向治療組合、定向治療是目前通常無法通過手術分離或已經擴散到腎外的腎癌的一線治療方法,是一種選擇。正在進行更多的研究,以確定哪些腎癌患者將從靶向療法、免疫療法或其組合中獲益最多。據美國癌症協會稱,早期研究表明,它們對靶向治療沒有反應,而且結果似乎很差。根據《世界癌症報告》,癌症的發病率將再增加 50%,到 2020 年有可能增加 1500 萬新病例。它還清楚地表明,政府和衛生專業人員的健康生活方式和公共衛生活動可以阻止這一趨勢並預防世界上三分之一的癌症。

區域展望

全球腎癌診斷和治療市場是根據對市場增長有顯著貢獻的地理區域進行分析的。市場報告包括北美(美國和加拿大)、歐洲(英國、德國、意大利、西班牙、法國和其他歐洲)、亞太地區(中國、日本、印度和其他亞太地區)和其他地區(RoW)。分為和分析。據估計,北美在全球腎癌市場中佔有很大份額。就收入而言,隨著政府加強該地區醫療保健設施的舉措增加,北美是全球腎癌市場中市場份額最高的國家之一。在北美,與推動區域增長的其他地區相比,患有癌症和慢性病的患者更多。預計歐洲將佔全球腎癌市場的重要份額,亞太地區慢性病患者人數增加,腎癌患病率增加,區域醫療保健設施不斷加強。目的,預計利潤增長最快。

市場參與者展望

此外,該報告還分析了在全球腎癌診斷和治療市場中運營的各種參與者。報告中涉及的主要參與者是AbbVie Inc、AstraZeneca Plc、GlaxoSmithKline Plc、F。Hoffmann-LaRoche AG、Merck&Co.、Novartis Ag、Pfizer Inc為了在市場中生存,這些參與者採用了各種營銷策略,包括合併、收購、產品發佈和地域擴張。例如,Merck & Co. Inc.在 2019 年 4 月獲得了美國(FDA)食品和藥物管理局的批准,該藥物可用於治療晚期腎細胞癌(RCC)患者。批准基於 KEYNOTE-426 (NCT02853331)。

本報告涵蓋以下項目

  • 市場價值數據分析和預測。
  • 每個細分市場的年市場收入(以 100 萬美元為單位)。
  • 主要地理區域的國家分析。
  • 在全球氯甲烷市場運營的主要公司。根據數據的可用性,報告中還提供了與新產品發佈和相關新聞相關的信息。
  • 通過確定未來強勁增長的關鍵細分市場來分析業務戰略。
  • 市場進入和市場擴張策略分析。
  • 通過確定誰在市場上的位置來製定競爭策略。

本報告調查了全球腎癌診斷和治療市場,概述了市場,分析了市場增長和障礙、市場機會以及按癌症類型/診斷/治療/地區劃分的市場規模。它提供了系統信息,例如作為趨勢和預測、競爭條件以及主要公司的簡介。

目錄

第 1 章報告概述

第 2 章市場概覽和洞察

  • 調查範圍
  • 分析師洞察和當前市場趨勢
  • 規則

第 3 章競爭形勢

  • 公司股票分析
  • 重要的戰略分析
  • 主要公司分析

第 4 章市場決定因素

  • 動機
  • 抑制要因
  • 市場機會

第 5 章市場細分

  • 按癌症類型
    • 透明細胞 RCC(腎細胞癌)
    • 乳頭狀 RCC
    • 有色腎細胞
    • 尿路上皮癌/移行上皮癌
    • 其他腎癌(Wilms 瘤、腎肉瘤、集合管 RCC)
  • 按診斷方法
    • 活檢
    • 圖像檢查
    • 其他
  • 按治療
    • 靶向治療
    • 免疫療法
    • 冷凍消融

第 6 章區域分析

  • 北美
    • 美國
    • 加拿大
  • 歐洲
    • 英國
    • 德國
    • 意大利
    • 西班牙
    • 法國
    • 其他歐洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 其他亞太地區
  • 其他領域

第 7 章公司簡介

  • Abbvie, Inc.
  • Active Biotech Ab
  • Actuate Therapeutics, Inc.
  • Adaptimmune Therapeutics Plc
  • AstraZeneca Plc
  • Bayer AG
  • Cipla Limited
  • Eisai Co., Ltd.
  • Exelixis, Inc.
  • Genentech, Inc.
  • GlaxoSmithKline Plc
  • Hoffman-La Roche, Ltd.
  • Jazz Pharmaceuticals, Inc.
  • Merck & Co.
  • Novartis AG
  • Pfizer, Inc.
  • Prometheus Laboratories, Inc.
  • Sanofi S.A.
  • Takeda Pharmaceutical Co., Ltd.
目錄
Product Code: OMR2023389

Global Kidney Cancer Diagnostics and Therapeutics Market Size, Share & Trends Analysis Report By Cancer Type (Clear Cell RCC (Renal Cell Carcinoma), Papillary RCC, Chromophobe RCC, Urothelial carcinoma/Transitional cell carcinoma, and Other Kidney Cancers (Wilms tumor, Renal sarcoma, Collecting duct RCC)) By Diagnosis Method (Biopsy, Imaging Test, and Other), By Therapy (Targeted Therapy, Immunotherapy, and Cryoablation) Forecast 2021-2027

The global kidney cancer diagnostic and therapeutic market are growing at a considerable CAGR of 6.8% during the forecast period. The key features that drive the market growth include, increasing prevalence of kidney cancer, change in lifestyles such as smoking and drinking, less physical activity, and endorsement of novel drugs for the treatment of kidney cancer are the main factors driving the growth of the kidney cancer diagnostic and therapeutic market. In addition, for marketers, immunotherapies would rise as an opportunity in the market. Endless modernization in technological development and drug expansion in different therapies such as immunotherapy, and chemotherapy is expected to drive the growth of the global kidney cancer market. Development in treatment therapy such as immunotherapy is projected to generate huge prospects for the market.

Immunotherapy has less injuriousness than chemotherapy which creates it more suitable for senior people. Immunotherapy demonstrates a fast and constant reaction as compared to chemotherapy. an enormous number of the undiagnosed patient base in unused geographies will likely create profitable opportunities for the market dealers. However, growing preference for generic drugs and extraordinary costs related to branded drugs to treat kidney cancer are expected to restraint the market growth in the upcoming future.

Moreover, in May 2019, Pfizer Inc. received approval from the US (FDA) for the drug BAVENCIO (avelumab) Plus Inlyta that can be used for the treatment of patients having Advanced Renal Cell Carcinoma (RCC). The drug is one of the first anti-PD-L1 in combination with INLYTA. The Phase III study revealed a combination that considerably lowered the possibility of disease progression or death by 31% and protracted progression-free survival by 5.4 months for patients having advanced RCC compared with sunitinib.

Segmental Outlook

The global kidney cancer diagnostic and therapeutic market is segmented based on Therapy type, diagnosis method, and cancer type. Based on therapy type, the market is segmented into targeted therapy, immunotherapy, and cryoablation. Immunotherapy drug combinations, the combination of immune therapies with directed therapies, and directed therapies are now usually the first-line option to cure kidney cancers that cannot be separated by surgery or have spread outside the kidney. More research is being done to see which people with kidney cancer will benefit most from targeted therapy, immunotherapy, or combinations. According to the American cancer society, Initial studies seem to show that they do not respond as well to targeted therapy drugs and appear to have poorer outcomes. Cancer rates could further increase by 50%, to 15 million new cases by 2020, as per the World Cancer Report. It also delivers a clear indication that healthy lifestyles and public health action by governments and health specialists could stem this trend and prevent as many as one-third of cancers, globally.

Regional Outlook

The global kidney cancer diagnostic and therapeutic market is analyzed based on the geographical regions that are contributing significantly to the growth of the market. The market report covers the analysis of four major regions including North America (the US and Canada), Europe (UK, Germany, Italy, Spain, France, and Rest of Europe), Asia-Pacific (China, Japan, India, and the Rest of Asia-Pacific) and Rest of the World (RoW). North America is estimated to contribute a significant share in the global kidney cancer market. North America has one of the highest market shares in the global kidney cancer market in terms of revenue as the increase in government initiatives for the enhancement of healthcare facilities in the region. North America has more patients suffering from cancer and chronic diseases as compared to other regions that will increase regional growth. Europe has projected to contribute considerable revenue share in the global kidney cancer market, and the Asia Pacific is expected to have the fastest growth in terms of revenue, due to the increase in the number of patients having chronic diseases, the prevalence of kidney cancer, and an increase in government inventiveness for the enhancement of healthcare facilities in the region.

Global Kidney Cancer Diagnostics and Therapeutics Market Growth by Region, 2020-2027

Source: OMR Global

Market Players Outlook

Further, the report covers the analysis of various players operating in the global kidney cancer diagnostic and therapeutic market. Some of the major players covered in the report include AbbVie Inc, AstraZeneca Plc, GlaxoSmithKline Plc, F. Hoffmann-La Roche AG, Merck & Co., Novartis Ag, Pfizer Inc. To survive in the market, these players adopt different marketing strategies such as a merger, acquisitions, product launches, and geographical expansion. For instance, In April 2019, Merck & Co. Inc. received the US (FDA) Food and Drug Administration approval for the drug pembrolizumab that can be used for the treatment of patients having advanced renal cell carcinoma (RCC). The approval was based on KEYNOTE-426 (NCT02853331).

The Report Covers

  • Market value data analysis of 2020 and forecast to 2027.
  • Annualized market revenues ($ million) for each market segment.
  • Country-wise analysis of major geographical regions.
  • Key companies operating in the global kidney cancer diagnostic and therapeutic market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
  • Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
  • Analysis of market-entry and market expansion strategies.
  • Competitive strategies by identifying 'who-stands-where in the market.

Table of Contents

1. Report Summary

  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Geography

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion
  • 2.3. Regulations

3. Competitive Landscape

  • 3.1. Company Share Analysis
  • 3.2. Key Strategy Analysis
  • 3.3. Key Company Analysis
      • 3.3.1.1. Overview
      • 3.3.1.2. Financial Analysis
      • 3.3.1.3. SWOT Analysis
      • 3.3.1.4. Recent Developments

4. Market Determinants

  • 4.1. Motivators
  • 4.2. Restraints
  • 4.3. Opportunities

5. Market Segmentation

  • 5.1. Global Kidney Cancer Therapeutics & Diagnostics Market by Cancer Type
    • 5.1.1. Clear Cell RCC (Renal Cell Carcinoma)
    • 5.1.2. Papillary RCC
    • 5.1.3. Chromophobe RCC
    • 5.1.4. Urothelial Carcinoma/Transitional Cell Carcinoma
    • 5.1.5. Other Kidney Cancers (Wilms Tumor, Renal Sarcoma, Collecting Duct RCC)
  • 5.2. Global Kidney Cancer Therapeutics & Diagnostics Market by Diagnosis Method
    • 5.2.1. Biopsy
    • 5.2.2. Imaging Test
    • 5.2.3. Other
  • 5.3. Global Kidney Cancer Therapeutics & Diagnostics Market by Therapy
    • 5.3.1. Targeted Therapy
    • 5.3.2. Immunotherapy
    • 5.3.3. Cryoablation

6. Regional Analysis

  • 6.1. North America
    • 6.1.1. United States
    • 6.1.2. Canada
  • 6.2. Europe
    • 6.2.1. UK
    • 6.2.2. Germany
    • 6.2.3. Italy
    • 6.2.4. Spain
    • 6.2.5. France
    • 6.2.6. Rest of Europe
  • 6.3. Asia-Pacific
    • 6.3.1. China
    • 6.3.2. India
    • 6.3.3. Japan
    • 6.3.4. Rest of Asia-Pacific
  • 6.4. Rest of the World

7. Company Profiles

  • 7.1. Abbvie, Inc.
  • 7.2. Active Biotech Ab
  • 7.3. Actuate Therapeutics, Inc.
  • 7.4. Adaptimmune Therapeutics Plc
  • 7.5. AstraZeneca Plc
  • 7.6. Bayer AG
  • 7.7. Cipla Limited
  • 7.8. Eisai Co., Ltd.
  • 7.9. Exelixis, Inc.
  • 7.10. Genentech, Inc.
  • 7.11. GlaxoSmithKline Plc
  • 7.12. Hoffman-La Roche, Ltd.
  • 7.13. Jazz Pharmaceuticals, Inc.
  • 7.14. Merck & Co.
  • 7.15. Novartis AG
  • 7.16. Pfizer, Inc.
  • 7.17. Prometheus Laboratories, Inc.
  • 7.18. Sanofi S.A.
  • 7.19. Takeda Pharmaceutical Co., Ltd.

LIST OF TABLES

1 GLOBAL KIDNEY CANCER THERAPEUTICS & DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY CANCER TYPE, 2020-2027 ($ MILLION)

2 GLOBAL CLEAR CELL RCC (RENAL CELL CARCINOMA ) MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)

3 GLOBAL PAPILLARY RCC MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)

4 GLOBAL CHROMOPHOBE RCC MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)

5 GLOBAL UROTHELIAL CARCINOMA/TRANSITIONAL CELL CARCINOMA MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)

6 GLOBAL OTHER KIDNEY CANCERS MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)

7 GLOBAL KIDNEY CANCER THERAPEUTICS & DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS METHOD, 2020-2027 ($ MILLION)

8 GLOBAL BIOPSY MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)

9 GLOBAL IMAGING TEST MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)

10 GLOBAL OTHER MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)

11 GLOBAL KIDNEY CANCER THERAPEUTICS & DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY THERAPY, 2020-2027 ($ MILLION)

12 GLOBAL TARGETED THERAPY MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)

13 GLOBAL IMMUNOTHERAPY MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)

14 GLOBAL CRYOABLATION MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)

15 NORTH AMERICAN KIDNEY CANCER THERAPEUTICS & DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY CANCER TYPE, 2020-2027 ($MILLION)

16 NORTH AMERICAN KIDNEY CANCER THERAPEUTICS & DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS METHOD, 2020-2027 ($MILLION)

17 NORTH AMERICAN KIDNEY CANCER THERAPEUTICS & DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY THERAPY TYPE, 2020-2027 ($MILLION)

18 EUROPEAN KIDNEY CANCER THERAPEUTICS & DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY CANCER TYPE, 2020-2027 ($MILLION)

19 EUROPEAN KIDNEY CANCER THERAPEUTICS & DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS METHOD, 2020-2027 ($MILLION)

20 EUROPEAN KIDNEY CANCER THERAPEUTICS & DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY THERAPY TYPE, 2020-2027 ($MILLION)

21 ASIA-PACIFIC KIDNEY CANCER THERAPEUTICS & DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY CANCER TYPE, 2020-2027 ($MILLION)

22 ASIA-PACIFIC KIDNEY CANCER THERAPEUTICS & DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS METHOD, 2020-2027 ($MILLION)

23 ASIA-PACIFIC KIDNEY CANCER THERAPEUTICS & DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY THERAPY TYPE, 2020-2027 ($MILLION)

24 REST OF THE WORLD KIDNEY CANCER THERAPEUTICS & DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY CANCER TYPE, 2020-2027 ($MILLION)

25 REST OF THE WORLD KIDNEY CANCER THERAPEUTICS & DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS METHOD, 2020-2027 ($MILLION)

26 REST OF THE WORLD KIDNEY CANCER THERAPEUTICS & DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY THERAPY TYPE, 2020-2027 ($MILLION)

LIST OF FIGURES

  • 1. GLOBAL KIDNEY CANCER THERAPEUTICS & DIAGNOSTICS MARKET SHARE BY CANCER TYPE, 2020 VS 2027 (%)
  • 2. GLOBAL KIDNEY CANCER MARKET SHARE BY CANCER DIAGNOSIS METHOD, 2020 VS 2027 (%)
  • 3. GLOBAL KIDNEY CANCER MARKET SHARE BY CANCER THERAPY TYPE, 2020 VS 2027 (%)
  • 4. GLOBAL CLEAR CELL RCC MARKET SHARE ANALYSIS BY REGION, 2020 VS 2027 (%)
  • 5. GLOBAL PAPILLARY RCC MARKET SHARE ANALYSIS BY REGION, 2020 VS 2027 (%)
  • 6. GLOBAL CHROMOPHOBE RCC MARKET SHARE ANALYSIS BY REGION, 2020 VS 2027 (%)
  • 7. GLOBAL UROTHELIAL CARCINOMA/TRANSITIONAL CELL CARCINOMA MARKET SHARE ANALYSIS BY REGION, 2020 VS 2027 (%)
  • 8. GLOBAL OTHER KIDNEY CANCERS MARKET SHARE ANALYSIS BY REGION, 2020 VS 2027 (%)
  • 9. GLOBAL KIDNEY CANCER THERAPEUTICS & DIAGNOSTICS MARKET SHARE ANALYSIS BY REGION, 2020 VS 2027 (%)
  • 10. GLOBAL BIOPSY MARKET SHARE ANALYSIS BY REGION, 2020 VS 2027 (%)
  • 11. GLOBAL IMAGING TEST MARKET SHARE ANALYSIS BY REGION, 2020 VS 2027 (%)
  • 12. GLOBAL OTHER MARKET SHARE ANALYSIS BY REGION, 2020 VS 2027 (%)
  • 13. GLOBAL TARGETED THERAPY MARKET SHARE ANALYSIS BY REGION, 2020 VS 2027 (%)
  • 14. GLOBAL IMMUNOTHERAPY MARKET SHARE ANALYSIS BY REGION, 2020 VS 2027 (%)
  • 15. GLOBAL CRYOABLATION MARKET SHARE ANALYSIS BY REGION, 2020 VS 2027 (%)
  • 16. US KIDNEY CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, 2020-2027 ($ MILLION)
  • 17. CANADA KIDNEY CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, 2020-2027 ($ MILLION)
  • 18. UK KIDNEY CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, 2020-2027 ($ MILLION)
  • 19. FRANCE KIDNEY CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, 2020-2027 ($ MILLION)
  • 20. GERMANY KIDNEY CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, 2020-2027 ($ MILLION)
  • 21. ITALY KIDNEY CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, 2020-2027 ($ MILLION)
  • 22. SPAIN KIDNEY CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, 2020-2027 ($ MILLION)
  • 23. REST OF EUROPE KIDNEY CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, 2020-2027 ($ MILLION)
  • 24. INDIA KIDNEY CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, 2020-2027 ($ MILLION)
  • 25. CHINA KIDNEY CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, 2020-2027 ($ MILLION)
  • 26. JAPAN KIDNEY CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, 2020-2027 ($ MILLION)
  • 27. REST OF ASIA-PACIFIC KIDNEY CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, 2020-2027 ($ MILLION)
  • 28. REST OF THE WORLD KIDNEY CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, 2020-2027 ($ MILLION)